Bioxcel Therapeutics ( (BTAI) ) has released its Q3 earnings. Here is a breakdown of the information Bioxcel Therapeutics presented to its investors.
BioXcel Therapeutics, Inc. is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company focuses on drug re-innovation by leveraging existing approved drugs and clinically validated candidates to identify new therapeutic indications.
BioXcel Therapeutics announced its financial results for the third quarter of 2024, highlighting its ongoing advancement of pivotal Phase 3 trials for BXCL501, aimed at treating acute agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia. The company is also strengthening its intellectual property portfolio for IGALMI™, a sublingual film formulation.
Key financial metrics show that BioXcel Therapeutics recorded net revenue of $214 thousand for the third quarter of 2024, a decrease from the previous year, attributed to the timing of re-orders. However, the net revenue for the first nine months of 2024 showed an 89% increase compared to the same period in 2023. The company reported a significant reduction in research and development expenses, as well as selling, general, and administrative expenses, resulting in a net loss reduction to $13.7 million from $50.5 million in the previous year.
The company is actively pursuing its SERENITY and TRANQUILITY trials, aiming to expand its market presence for BXCL501. With the continued support of strategic trials and strengthening patent protection, BioXcel Therapeutics is positioning itself for future growth opportunities in the treatment of neurological conditions.
Looking forward, BioXcel Therapeutics remains committed to advancing its clinical programs and leveraging its artificial intelligence capabilities to develop innovative treatments. The management’s focus is on meeting the needs of patients and expanding market potential for its lead neuroscience assets.
